Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Key to cancer

<< Previous

Bullboard Posts

Next >>

Comment by Biobobon Nov 02, 2022 1:04pm

117 Views

Post# 35066884

RE:Key to cancer

This is a total sh..tshow. It think this will end in disgrace for our new CEO. Wrong set of skills for a biotech R&D company now it seems. Too much overhead, too much talk and little acheivements. I'm done with those guys and will be looking to submit a strategic review plan at the next AGM.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China